StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.61−0.05 (-8.28%)

Close on Nov 17, 2026Market cap $109.26MP/E –Yield –

Compass Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Compass Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$56.38M. For fiscal 2025 it was -$49.17M. The highest annual figure on record is -$21.23M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.17M–
FY2024Dec 31, 2024-$44.90M–
FY2023Dec 31, 2023-$40.65M–
FY2022Dec 31, 2022-$34.34M–
FY2021Dec 31, 2021-$21.23M–
FY2020Dec 31, 2020-$26.91M–
FY2019Dec 31, 2019-$32.21M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.91M–
Q1 FY2026Mar 31, 2026-$17.35M–
Q4 FY2025Dec 31, 2025-$13.25M–
Q3 FY2025Sep 30, 2025-$10.86M–
Q2 FY2025Jun 30, 2025-$11.83M–
Q1 FY2025Mar 31, 2025-$13.23M–
Q4 FY2024Dec 31, 2024-$9.16M–
Q3 FY2024Sep 30, 2024-$11.10M–
Q2 FY2024Jun 30, 2024-$10.75M–
Q1 FY2024Mar 31, 2024-$13.89M–
Q4 FY2023Dec 31, 2023-$12.36M–
Q3 FY2023Sep 30, 2023-$5.93M–
Q2 FY2023Jun 30, 2023-$10.12M–
Q1 FY2023Mar 31, 2023-$12.23M–
Q4 FY2022Dec 31, 2022-$10.70M–
Q3 FY2022Sep 30, 2022-$10.97M–
Q2 FY2022Jun 30, 2022-$4.54M–
Q1 FY2022Mar 31, 2022-$8.14M–
Q4 FY2021Dec 31, 2021-$5.44M–
Q3 FY2021Sep 30, 2021-$3.82M–
Q2 FY2021Jun 30, 2021-$6.24M–
Q1 FY2021Mar 31, 2021-$5.73M–
Q4 FY2020Dec 31, 2020-$6.66M–
Q3 FY2020Sep 30, 2020-$7.18M–
Q2 FY2020Jun 30, 2020-$5.30M–
Q1 FY2020Mar 31, 2020-$7.77M–
Q2 FY2019Sep 30, 2019-$6.73M–
Q1 FY2019Jun 30, 2019-$19.70M–

More Compass Therapeutics figures

See a number that looks wrong?